Prevalence of hepatitis C virus infection and its correlates in a rural area of southwestern China: a community-based cross-sectional study

Wanting Cheng,1,2,3 Ya Yang,1,2,3 Yibiao Zhou,1,2,3 Penglei Xiao,1,2,3 Yan Shi,1,2,3 Jianchuan Gao,1,2,3 Yue Chen,4 Song Liang,5,6 Wuli Yihuo,7 Xiuxia Song,1,2,3 Qingwu Jiang1,2,3

ABSTRACT

Objectives  Hepatitis C virus (HCV) infection is a major public health problem in southwestern China. Our aim of the study was to assess the prevalence of HCV infection and its correlates in the Yi population of this region.

Methods  A community-based survey was conducted to investigate sociodemographic characteristics and other associated factors for HCV infection in a rural area of southwestern China. Blood samples were collected and tested for antibodies to HCV. Anti-HCV positive samples were further assessed for HCV RNA.

Results  A total of 2558 participants aged ≥14 years were included in our analysis. Of them, 2.8% (95% CI 2.2% to 3.5%) were positive for HCV antibody. Multiple logistic regression analysis revealed that sex (male vs female: adjusted OR (aOR)=3.30, 95% CI 1.80 to 6.07), marital status (unmarried vs married: aOR=0.27, 95% CI 0.09 to 0.80), ever using injection drug (aOR=28.65, 95% CI 15.9 to 51.64) and ever having blood transfusion (aOR=7.64, 95% CI 1.94 to 30.16) were significantly associated with HCV infection (indicated by positive HCV antibody). Stratified analysis by HIV infection found that in HIV-negative individuals, sex (male vs female: aOR=3.84, 95% CI 1.88 to 7.85), ever using injection drug (aOR=22.15, 95% CI 8.45 to 58.04), having multiple sexual partners (aOR=2.57, 95% CI 1.26 to 5.23), and ever having blood transfusion (aOR=16.54, 95% CI 4.44 to 61.58) were significantly associated with HCV infection and in HIV-positive individuals, ever using injection drug (aOR=8.96, 95% CI 3.16 to 25.38) was associated with HCV infection.

Conclusion  The data suggested a higher risk of HCV infection in this area when compared with the rest of China and some unique associated factors. Rapid scale-up of targeted interventions are needed to prevent further transmission and consequent morbidities.

INTRODUCTION

Chronic infection with hepatitis C virus (HCV) is a major, growing public health concern and one of the leading causes of death globally.1 Hepatitis B virus and HCV infections accounted for 96% (95% CI 94% to 97%) of viral hepatitis-related mortality in 2003.1 There were estimated 1.75 million people newly infected with HCV worldwide in 2015, bringing the global total of people with hepatitis C infection to 71 million.2 Approximately 704 000 people died of hepatitis C in 2015.3 More than 90% chronic HCV infection can be cured by direct-acting antiviral medications.3 However, 75%–90% of those with HCV infection were unaware of the infection and received no treatment, which eventually led to progressive liver fibrosis, cirrhosis and an increased risk of liver cancer.4

Epidemiological data on HCV infection are critical for developing public health strategies towards HCV infection prevention, care and treatment. HCV infection has various transmission routes, of which the most important one is direct percutaneous exposures to blood (eg, transfusion or transplantation from infectious donors and injecting drug use).4 Evidence for sexual transmission of HCV is controversial.5 Injection drug use (IDU) has become the predominant route of HCV infection in China since the establishment of

Strengths and limitations of this study

► The study was conducted in a rural area of Yi ethnic minority in southwestern China where drug abuse is a serious problem.
► Estimates provided in this study were community-based, which suggested a high prevalence of hepatitis C virus (HCV) infection in the rural area of Yi ethnic minority.
► Positive HCV antibody as an indicator of HCV infection might overestimate the burden of HCV infection.
► Young men who looked for jobs elsewhere were not sampled, which might result in an underestimation of the prevalence of HCV infection.
► There was no verification of self-reported information.
a blood transfusion scrutiny system.\(^6\) The Yi Prefecture is along a major heroin trafficking route located in southwestern China, and is an endemic area for HIV.\(^7\)\(^8\)

HIV and HCV have overlapping transmission routes.\(^9\) Persons with HIV/HCV coinfected generally have more rapid progression of liver fibrosis, and the mortality of hepatocellular carcinoma is higher among coinfected patients than patients with HCV monoinfection.\(^4\)\(^10\)\(^–\)\(^12\)

Several studies have described the prevalence of HCV infection and its determinants among some Han populations such as IDUs and blood donors in China.\(^8\)\(^13\)\(^14\) However, to date, few studies were community-based and studied the Yi people. The primary purpose of this study was to investigate the prevalence of HCV infection and its associated factors in a rural area in Yi Prefecture. We also explored the association between HCV and HIV as well as HIV-HCV coinfection.

METHODS

Study area and population

The Yi Prefecture is located in Southwest of China. Most residents are Yi ethnicity, a minority group in China. Because of rugged mountainous terrains and sparsely scattered population, it remains an underdeveloped place in China.\(^15\) This region is noted for HIV epidemic because of drug trafficking through the neighbouring Yunnan Province.\(^16\) The study adopted a two-stage sampling scheme. First, three counties (P, Z and M) were selected from the Yi Prefecture on the basis of similar social demographic characters (such as gender structure, economic status, custom, education level and sanitary facility) as well as high prevalence of HIV infection. Second, four towns were randomly selected from three counties (A and B from P County, C from Z county and D from M county) with a total of 27 villages for the study (figure 1). All local residents aged≥26 years, who had lived there for more than 6 months, were invited to participate in the survey. Considering the local geographic characteristic and high authority of village chiefs, the village chiefs were asked for assistance in participants’ enrolment.

Data and blood sample collection

Our study was conducted during the period from October 2014 to August 2015. Experienced workers from the local Center for Disease Control (CDC) were further trained for the investigation. They informed all participants of the objectives, contents and potential risks of this survey. Participants were personally interviewed using a structured questionnaire, which covered demographic characteristics (including age, sex, ethnicity, marital status, education, occupation and annual income), sexual behaviour (including age of first sex, frequency of condom use and multiple sexual partners), drug misuse behaviour (including age of starting drug misuse, mode of drug misuse in the past 6 months and sharing syringe in the past 3 months) and history of blood transfusion.

Each participant had a finger prick and provided about 1 mL of blood for testing HCV antibody by using the Diagnostic Kit for HCV antibody (Colloidal Gold) (product of Livzon Pharmaceutical Group, Zhuhai, P. R. China, batch number: 2014080200, 50 persons per kit). Colloidal gold kits are simple, economic and reliable methods for detecting HCV antibody.\(^17\) Product specifications show that the sensitivity and specificity of the colloidal gold kits are both higher than 95%. A 5 mL blood sample was collected from those with a positive screening result and transported to local township hospitals. Whole blood was centrifuged at 1000 rpm for 5 min and plasma was separated and stored at constant temperature of −20°C within 8 hours, and then were transported in ice to Shanghai for HCV RNA testing by using the HCV RNA Quantitative Fluorescence Diagnostic Kit (PCR Fluorescence Probing, level of detection: 25 IU/mL) (Sansure Biotech, San Diego, USA and Changsha, China).

Ethical considerations

The procedures of this study were reviewed and approved by the Ethical Review Committee of School of Public Health, Fudan University. Each potential participant was asked to sign a written informed consent. If the participants were younger than 18 years of age, their parents were asked to sign the written informed consent for them. At the end of the study, participants with positive results were informed of the results and provided with appropriate medical consultations, further examinations and treatments.

Statistical analysis

Data were entered using the EpiData software (V.3.1; the EpiData Association) and were imported to SPSS statistical package (V.17.0; IBM SPSS Institute) for management and analysis. Descriptive data were generated for sociodemographic variables. The proportions of positive anti-HCV and HCV RNA were calculated together with their 95% CIs. In univariate analysis, Pearson \(\chi^2\) test or Fisher’s exact test was used to test the significance of associations between HCV infection and associated factors and crude ORs with 95% CIs were calculated. We then employed a stepwise selection approach (p value of entry ≤0.05, p value of removal ≥0.1) to produce a final multivariable model, which included important variables associated with HCV infection. Adjusted ORs and 95% CIs were calculated for identified associated factors. Stratified analysis was performed for individuals with and without HIV infection. All p values were reported as being two sided.

RESULTS

A total of 3164 individuals were recruited into our study. As local Yi indigenous culture considers 14 years of age as the start of adulthood for permitting sexual behaviours, the current analysis included 2558 individuals aged 14 years or older, who completed both the survey questionnaire...
and HCV testing. Table 1 shows the demographic characteristics of the study participants. Participants were predominantly Yi people (97%). Most participants were women (65.1%), illiterate (64.7%), married (74.8%) and farmers (91.6%).

Table 2 shows the results for positive HCV antibody and HCV RNA testing. Of the participants, 2.8% (95% CI 2.2% to 3.5%) were positive for HCV antibody. Out of 71, 46 anti-HCV positive participants provided blood samples for HCV RNA testing, and 71.7% (95% CI 56.5% to 84.0%) of them were HCV RNA positive.

After adjustment for covariates, multiple logistic regression analysis showed that increased risks of HCV infection, indicated by positive HCV antibody, were significantly associated with sex (male vs female: aOR=3.30, 95% CI 1.80 to 6.07), marital status (unmarried vs married: aOR=0.27, 95% CI 0.09 to 0.80), ever using injection drug (aOR=28.65, 95% CI 15.9 to 51.64) and ever having blood transfusion (aOR=7.64, 95% CI 1.94 to 30.16) (table 3).

Tables 4 and 5 show the results for the correlates of HCV infection with and without HIV infection. The prevalence of HCV infection, indicated by positive HCV antibody, was higher among HIV-infected individuals than HIV-negative individuals (24.0%, 95% CI 16.6% to 31.5% vs 1.6%, 95% CI 1.1% to 2.2%). For HIV-negative participants, significant predictors for HCV infection were...
sex (male vs female: aOR=3.84, 95% CI 1.88 to 7.85), ever using injection drug (aOR=22.15, 95% CI 8.45 to 58.04), having multiple sexual partners (aOR=2.57, 95% CI 1.26 to 5.23) and ever having blood transfusion (aOR=16.54, 95% CI 4.44 to 61.58). Among HIV-infected participants, however, only ever using injection drug (aOR=8.96, 95% CI 3.16 to 25.38) was significantly associated with an increased risk of HCV infection.

**DISCUSSION**

In our study, 2.8% (95% CI 2.2% to 3.5%) of residents aged ≥14 years were positive for HCV antibody. The prevalence was slightly lower (2.2%) when children were included. The prevalence of HCV infection, indicated by positive HCV antibody, in this region was significantly higher than the prevalence among residents aged 15–59 years in China (0.62%).18 This difference may be explained, at least in part, by a high proportion of ever using injection drug (3.48%) in the study area. Our study sites are adjacent to the ‘Golden Triangle’ where large amounts of illicit heroin are produced and traded, resulting in a serious epidemic of drug abuse. This is also supported by a study (HCV infection: 4.3%) conducted in a rural area in Yunnan Province, China (2012), which was also noted for drug abuse.19

Consistent with previous studies, IDUs had a higher prevalence of HCV infection (39.3%).20 21 HCV is transmitted primarily through direct percutaneous routes, including sharing contaminated needles or syringes.22 In the past few years, some countries have implemented effective needle or syringe exchange programmes and showed a substantial decline of HCV infection.23 Opiate substitution therapy and provision of antiviral therapy in IDUs also lead to a reduction of HCV transmission.24 Promotion of opiate substitution therapy and high coverage of needle and syringe programmes can substantially reduce the risk of HCV transmission among IDUs.25–27 China has launched methadone maintenance treatment (MMT) and needle and syringe exchange programmes (NSEP) for IDUs in response to HIV epidemics. The MMT is expanding, with a support from multiple ministries of the central government, while the NSEP has received less support both politically and financially.28 Therefore, a scale-up of the NSEP and integration with other harm reduction projects as well as a removal of the societal and political barriers should be a priority for the Chinese health authorities. Routine monitoring and surveillance of HCV infection at MMT clinics would also provide valuable information for evaluating the effects of MMT and NSEP interventions.29 Previous studies reported that treatment uptake among IDUs remained very low, making IDUs a priority in HCV treatment programmes.30

### Table 1: Demographic characteristics of the participants aged ≥14 years

| Characteristic       | No  | %     |
|----------------------|-----|-------|
| Total                | 2558|       |
| Township             |     |       |
| A                    | 524 | 20.5  |
| B                    | 520 | 20.3  |
| C                    | 967 | 37.8  |
| D                    | 547 | 21.4  |
| Sex                  |     |       |
| Female               | 1664| 65.1  |
| Male                 | 894 | 34.9  |
| Age (years)          |     |       |
| 14–24                | 409 | 16.0  |
| 25–34                | 577 | 22.6  |
| 35–44                | 760 | 29.7  |
| 45–54                | 545 | 21.3  |
| ≥55                  | 267 | 10.4  |
| Ethnicity            |     |       |
| Han                  | 70  | 2.7   |
| Yi                   | 2481| 97.0  |
| Other                | 3   | 0.1   |
| Missing              | 4   | 0.2   |
| Education            |     |       |
| Illiterate           | 1656| 64.7  |
| Primary school and above | 900 | 35.2 |
| Missing              | 2   | 0.1   |
| Occupation           |     |       |
| Farmer               | 2344| 91.6  |
| Student              | 155 | 6.1   |
| Other                | 37  | 1.4   |
| Missing              | 22  | 0.9   |
| Annual income        |     |       |
| <1000                | 405 | 15.8  |
| 1000–2999            | 906 | 35.4  |
| 3000–4999            | 590 | 23.1  |
| 5000–9999            | 309 | 12.1  |
| ≥10000               | 324 | 12.7  |
| Missing              | 24  | 0.9   |
| Marital status       |     |       |
| Unmarried            | 420 | 16.4  |
| Married              | 1913| 74.8  |
| Divorced/Widowed     | 222 | 8.7   |
| Missing              | 3   | 0.1   |

### Table 2: Proportions of positive hepatitis C virus (HCV) antibody and HCV RNA in participants aged ≥14 years

| Characteristic         | No  | Positive cases | Positive rate (95% CI) |
|------------------------|-----|----------------|------------------------|
| HCV antibody           | 2558| 71             | 2.8% (2.2 to 3.5)      |
| HCV RNA                | 46  | 33             | 71.7% (56.5 to 84.0)   |
| Characteristic | No of participants | No of infections (%) | cOR (95% CI) | aOR (95% CI) |
|---------------|--------------------|----------------------|--------------|--------------|
| **Township**  |                    |                      |              |              |
| A             | 524                | 4 (0.8)              | 0.12 (0.042 to 0.34)** |              |
| B             | 520                | 11 (2.1)             | 0.34 (0.17 to 0.67)** |              |
| C             | 967                | 23 (2.4)             | 0.38 (0.22 to 0.65)** |              |
| D             | 547                | 33 (6)               |              |              |
| **Sex**       |                    |                      |              |              |
| Female        | 1664               | 17 (1)               | 1            | 1            |
| Male          | 894                | 54 (6)               | 6.23 (3.59 to 10.81)** | 3.30 (1.80 to 6.07)** |
| **Age (years)**|                    |                      |              |              |
| 14–24         | 409                | 4 (1)                | 0.23 (0.078 to 0.66)** |              |
| 25–34         | 577                | 24 (4.2)             | 1            |              |
| 35–44         | 760                | 31 (4.1)             | 0.98 (0.57 to 1.69) |              |
| 45–54         | 545                | 10 (1.8)             | 0.43 (0.20 to 0.91)* |              |
| ≥55           | 267                | 2 (0.7)              | 0.17 (0.41 to 0.74)* |              |
| **Ethnicity** |                    |                      |              |              |
| Han           | 70                 | 1 (1.4)              |              |              |
| Yi            | 2481               | 70 (2.8)             |              |              |
| Other         | 3                  | 0 (0.0)              |              |              |
| **Education** |                    |                      |              |              |
| Illiterate    | 1656               | 38 (2.3)             | 1            |              |
| Primary school or above | 900 | 33 (3.7)             | 1.62 (1.01 to 2.60)* |              |
| **Occupation**|                    |                      |              |              |
| Farmer        | 2344               | 70 (3)               |              |              |
| Student       | 155                | 0 (0.0)              |              |              |
| Other         | 37                 | 1 (2.7)              |              |              |
| **Annual income** |     |                      |              |              |
| <1000         | 405                | 12 (3)               | 1            |              |
| 1000–2999     | 906                | 28 (3.1)             | 1.04 (0.53 to 2.08) |              |
| 3000–4999     | 590                | 18 (3.1)             | 1.03 (0.49 to 2.16) |              |
| 5000–9999     | 309                | 8 (2.6)              | 0.87 (0.35 to 2.16) |              |
| ≥10000        | 324                | 5 (1.5)              | 0.51 (0.18 to 1.47) |              |
| **Marital status** |     |                      |              |              |
| Continued     |                    |                      |              |              |
| Characteristic                  | No of participants | No of infections (%) | cOR (95% CI)       | aOR (95% CI)       |
|--------------------------------|--------------------|----------------------|--------------------|--------------------|
| Unmarried                      | 420                | 4 (1.0)              | 0.28 (0.10 to 0.78)*| 0.27 (0.093 to 0.80)*|
| Married                        | 1913               | 63 (3.3)             | 1                   | 1                   |
| Divorced/Widowed               | 222                | 4 (1.8)              | 0.54 (0.19 to 1.50) | 0.45 (0.15 to 1.42) |
| Ever using injection drug      |                    |                      |                     |                     |
| No                             | 2469               | 36 (1.5)             | 1                   | 1                   |
| Yes                            | 89                 | 35 (39.3)            | 43.80 (25.58 to 75.00)**| 28.65 (15.9 to 51.64)**|
| Having multiple sexual partners|                    |                      |                     |                     |
| No                             | 2163               | 40 (1.8)             | 1                   |                     |
| Yes                            | 395                | 31 (7.8)             | 4.52 (2.79 to 7.32)**|                     |
| Condom use                     |                    |                      |                     |                     |
| Always                         | 629                | 15 (2.4)             | 0.93 (0.50 to 1.70) |                     |
| Occasionally                   | 489                | 19 (3.9)             | 1.53 (0.87 to 2.69) |                     |
| Never                          | 1440               | 37 (2.6)             | 1                   |                     |
| Ever having blood transfusion  |                    |                      |                     |                     |
| No or unknown                  | 2534               | 67 (2.6)             | 1                   | 1                   |
| Yes                            | 24                 | 4 (16.7)             | 7.36 (2.45 to 22.14)**| 7.64 (1.94 to 30.16)**|
| HIV infection status           |                    |                      |                     |                     |
| Negative                       | 2428               | 40 (1.6)             | 1                   |                     |
| Positive                       | 129                | 31 (24.0)            | 18.88 (11.33 to 31.47)**|                     |

*p<0.05; **p<0.01.

aOR, adjusted OR; cOR, crude OR.
| Characteristic          | No of participants | No of infections (%) | cOR (95% CI)    | aOR (95% CI)    |
|-------------------------|--------------------|----------------------|----------------|----------------|
| Total                   | 2428               | 40 (1.6)             |                |                |
| **Township**            |                    |                      |                |                |
| A                       | 510                | 2 (0.4)              | 0.13 (0.030 to 0.59)* |                |
| B                       | 519                | 11 (2.1)             | 0.73 (0.33 to 1.62) |                |
| C                       | 913                | 13 (1.4)             | 0.49 (0.23 to 1.05) |                |
| D                       | 486                | 14 (2.9)             | 1              |                |
| **Sex**                 |                    |                      |                |                |
| Female                  | 1607               | 12 (0.7)             | 1              | 1              |
| Male                    | 821                | 28 (3.4)             | 4.69 (2.37 to 9.28)* | 3.84 (1.88 to 7.85)** |
| **Age (years)**         |                    |                      |                |                |
| 14–24                   | 400                | 2 (0.5)              | 0.19 (0.042 to 0.83)* |                |
| 25–34                   | 536                | 14 (2.6)             | 1              |                |
| 35–44                   | 697                | 14 (2)               | 0.76 (0.36 to 1.62) |                |
| 45–54                   | 529                | 8 (1.5)              | 0.57 (0.24 to 1.38) |                |
| 55                      | 266                | 2 (0.8)              | 0.28 (0.064 to 1.25) |                |
| **Ethnicity**           |                    |                      |                |                |
| Han                     | 68                 | 0 (0.0)              |                |                |
| Yi                      | 2353               | 40 (1.7)             |                |                |
| Other                   | 3                  | 0 (0.0)              |                |                |
| **Education level**     |                    |                      |                |                |
| Illiterate              | 1575               | 23 (1.5)             | 1              |                |
| Primary school and above| 851                | 17 (2)               | 1.38 (0.73 to 2.59) |                |
| **Occupation**          |                    |                      |                |                |
| Farmer                  | 2216               | 40 (1.8)             |                |                |
| Student                 | 154                | 0 (0.0)              |                |                |
| Other                   | 36                 | 0 (0.0)              |                |                |
| **Annual income**       |                    |                      |                |                |
| <1000                   | 386                | 7 (1.8)              | 1              |                |
| 1000–2999               | 846                | 15 (1.8)             | 0.98 (0.40 to 2.42) |                |
| 3000–4999               | 557                | 9 (1.6)              | 0.89 (0.33 to 2.41) |                |
| 5000–9999               | 294                | 6 (2)                | 1.13 (0.38 to 3.39) |                |
| ≥10 000                 | 321                | 3 (0.9)              | 0.51 (0.13 to 1.99) |                |

Continued
### Table 4  Continued

| Characteristic                        | No of participants | No of infections (%) | cOR (95% CI)      | aOR (95% CI)      |
|---------------------------------------|--------------------|----------------------|-------------------|-------------------|
| **Marital status**                    |                    |                      |                   |                   |
| Unmarried                             | 401                | 1 (0.2)              | 0.12 (0.016 to 0.86)* |                   |
| Married                               | 1823               | 38 (2.1)             | 1                 |                   |
| Divorced/Widowed                      | 201                | 1 (0.5)              | 0.24 (0.032 to 1.72) |                   |
| **Ever using injection drug**         |                    |                      |                   |                   |
| No                                    | 2401               | 31 (1.3)             | 1                 | 1                 |
| Yes                                   | 27                 | 9 (33.3)             | 38.23 (15.93 to 91.71)* | 22.15 (8.45 to 58.04)** |
| **Having multiple sexual partners**   |                    |                      |                   |                   |
| No                                    | 2074               | 24 (1.2)             | 1                 | 1                 |
| Yes                                   | 354                | 16 (4.5)             | 4.04 (2.13 to 7.70)* | 2.57 (1.26 to 5.23)** |
| **Condom use**                        |                    |                      |                   |                   |
| Always                                | 599                | 10 (1.7)             | 1.20 (0.56 to 2.60) |                   |
| Occasionally                          | 466                | 11 (2.4)             | 1.71 (0.81 to 3.62) |                   |
| Never                                 | 1363               | 19 (1.4)             | 1                 |                   |
| **Ever having blood transfusion**     |                    |                      |                   |                   |
| No or unknown                         | 2407               | 37 (1.5)             | 1                 | 1                 |
| Yes                                   | 21                 | 3 (14.3)             | 10.68 (3.01,37.81)* | 16.54 (4.44 to 61.58)** |

*p<0.05; **p<0.01.

aOR, adjusted OR; cOR, crude OR.
| Characteristic | No of participants | No of infections (%) | cOR (95% CI) | aOR (95% CI) |
|---------------|--------------------|----------------------|--------------|--------------|
| **Total**     | 129                | 31 (24)              |              |              |
| **Township**  |                    |                      |              |              |
| A             | 14                 | 2 (14.3)             | 0.36 (0.073 to 1.77) |              |
| B             | 1                  | 0 (0.0)              |              |              |
| C             | 54                 | 10 (18.5)            | 0.49 (0.204 to 1.18) |              |
| D             | 60                 | 19 (31.7)            | 1            |              |
| **Sex**       |                    |                      |              |              |
| Female        | 56                 | 5 (8.9)              | 1            |              |
| Male          | 73                 | 26 (35.6)            | 5.64 (2.00 to 15.90)** |              |
| **Age (years)** |                  |                      |              |              |
| 14–24         | 9                  | 2 (22.2)             | 0.89 (0.16 to 4.97) |              |
| 25–34         | 41                 | 10 (24.4)            | 1            |              |
| 35–44         | 62                 | 17 (27.4)            | 1.17 (0.47 to 2.90) |              |
| 45–54         | 16                 | 2 (12.5)             | 0.44 (0.086 to 2.29) |              |
| ≥55           | 1                  | 0 (0.0)              |              |              |
| **Ethnicity** |                    |                      |              |              |
| Han           | 2                  | 1 (50)               |              |              |
| Yi            | 127                | 30 (23.6)            |              |              |
| Other         | 0                  | 0 (0.0)              |              |              |
| **Education level** |            |                      |              |              |
| Illiterate    | 80                 | 15 (18.8)            | 1            |              |
| Primary school and above | 49             | 16 (32.7)            | 2.10 (0.93 to 4.77) |              |
| **Occupation** |                  |                      |              |              |
| Farmer        | 127                | 30 (23.6)            |              |              |
| Student       | 1                  | 0 (0.0)              |              |              |
| Other         | 1                  | 1 (100)              |              |              |
| **Annual income** |                |                      |              |              |
| <1000         | 19                 | 5 (26.3)             | 1            |              |
| 1000–2999     | 59                 | 13 (22)              | 0.79 (0.24 to 2.61) |              |
| 3000–4999     | 33                 | 9 (27.3)             | 1.05 (0.29 to 3.76) |              |
| 5000–9999     | 15                 | 2 (13.3)             | 0.43 (0.07 to 2.61) |              |
| ≥10000        | 3                  | 2 (66.7)             | 5.60 (0.41 to 76.05) |              |

Continued
| Characteristic                      | No of participants | No of infections (%) | cOR (95% CI) | aOR (95% CI) |
|------------------------------------|--------------------|----------------------|--------------|--------------|
| **Marital status**                 |                    |                      |              |              |
| Unmarried                          | 19                 | 3 (15.8)             | 0.48 (0.13 to 1.79) |              |
| Married                            | 89                 | 25 (28.1)            | 1            |              |
| Divorced/Widowed                   | 21                 | 3 (14.3)             | 0.43 (0.12 to 1.58) |              |
| **Ever using injection drug**      |                    |                      |              |              |
| No                                 | 67                 | 5 (7.5)              | 1            | 1            |
| Yes                                | 62                 | 26 (41.9)            | 8.96 (3.16 to 25.38)** | 8.96 (3.16 to 25.38)** |
| **Having multiple sexual partners**|                    |                      |              |              |
| No                                 | 88                 | 16 (18.2)            | 1            |              |
| Yes                                | 41                 | 15 (36.6)            | 2.60 (1.13 to 5.98)* |              |
| **Condom use**                     |                    |                      |              |              |
| Always                             | 29                 | 5 (17.2)             | 0.68 (0.23 to 2.05) |              |
| Occasionally                       | 23                 | 8 (34.8)             | 1.75 (0.64 to 4.79) |              |
| Never                              | 77                 | 18 (23.4)            | 1            |              |
| **Ever having blood transfusion**  |                    |                      |              |              |
| No or unknown                      | 126                | 30 (23.8)            | 1            |              |
| Yes                                | 3                  | 1 (33.3)             | 1.60 (0.14 to 18.27) |              |

*p<0.05; **p<0.01.
aOR, adjusted OR; cOR, crude OR.
Individuals who have ever undergone a blood transfusion have a higher risk of HCV infection. Blood transfusion was one of the main routes of HCV transmission. China has taken steps to halt illegal blood collection, contributing to a decrease of new HCV infections. However, care for patients with chronic HCV infection is an ongoing challenge. Men had a higher prevalence of HCV infection than women, probably because drug misuse was more common in men (8.3%) than women (0.9%) in our study. Similar results were found in Poland.33 Age was not independently associated with HCV infection, which is inconsistent with results from other studies,34 35 and different epidemiological profiles might be a reason.36 For example, nosocomial infection was a predominant risk factor in Taiwan, which is age related.34 There were no significant differences in the distributions of ethnicity, education level, occupation and annual income between HCV-positive and HCV-negative individuals. Our study population was predominantly Yi people (97%) with similar sociodemographic background and lifestyle. Married individuals had a higher prevalence of HCV infection as evidenced by previous studies.3 5 37

The prevalence of HCV/HIV coinfection was 1.2% in the current study, equivalent to 24% of HCV in HIV-positive people. Results of the stratified analysis suggested that the prevalence of HCV in HIV-positive individuals was much higher than that in HIV-negative ones. A further comparison showed that HIV-positive compared with HIV-negative individuals had a constantly higher prevalence of HCV infection across all subgroups, which is likely resulted from depressed immunity due to HIV infection.38 Another possible explanation is that people at higher risk for HIV infection is also at higher risk for HCV infection.11 These results highlighted the necessity of routine HCV testing for all HIV-infected individuals, and also suggested that preventing HIV infection should be included as a part of HCV control strategies.

Among HIV-positive people, ever using injection drug was the only significant factor for HCV infection. A strong positive correlation has been reported between injection drug use and HIV/HCV coinfection.39 In our study, of the 31 subjects with the coinfection, twenty-six (83.9%) were ever IDUs. Having multiple sexual partners is a well-defined risk factor for HCV infection, however, it was not significant in HIV-infected individuals. Having multiple sexual partners is less important for HCV infection as compared with ever using injection drug in HIV-infected individuals.39

There are several limitations in this study. We used anti-HCV as an indicator for HCV infection, and there might be some false-positive results. Fifteen percent to 50% of patients with acute HCV infection clear HCV spontaneously.23 Our estimate for the prevalence of HCV infection could be conservative, because many young men who looked for jobs elsewhere were a high-risk population for drug abuse and were not able to participate in the study. In addition, the history of drug abuse and other high-risk behaviours relied on self-reporting with no further verification, which might result in a misclassification bias for the estimation of associations between study factors and HCV infection. The size of HIV-infected people was small and there might be lack of an adequate statistical power to detect certain associations. The cross-sectional design did not allow us to know the causal relationship between associated factors and HCV infection.

Conclusion
Our results revealed a high risk of HCV infection, indicated by positive HCV antibody and its significant associations with drug abuse, sex, marital status and blood transfusion. We also found that the correlates of HCV infection varied in HIV-negative and HIV-positive individuals. It is vital to implement comprehensive and effective intervention programmes to reduce the risk of HCV transmission and achieve adequate access to HCV treatment, especially for people who are IDUs.

Author affiliations
1Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China
2Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai, China
3Centre for Tropical Disease Research, Fudan University, Shanghai, China
4School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada
5Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, USA
6Emerging Pathogens Institute, University of Florida, Gainesville, USA
7Puge Centre for Disease Prevention and Control, Sichuan, China

Acknowledgements We would like to acknowledge the staff from the local CDC for questionnaire investigation and blood testing, and the local government officials for their support in data and sample collection.

Contributors WC participated in the conception and design of study, data collection, analysis and interpretation, and the preparation of the manuscript. YY participated in the conception and design of study and data collection, analysis and interpretation. YZ, XS and QJ conceived and designed the experiments and revised the manuscript draft. YZ, XS, PY, JS, JG, YY and WS participated in the data collection. YC and SL contributed to the critical review of manuscript. All authors read and approved the final manuscript.

Funding This work was supported by The Fourth Round of Three-Year Public Health Action Plan of Shanghai, China (grant number 15GWZK0101).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The procedures of this study were reviewed and approved by the Ethical Review Committee of School of Public Health, Fudan University. All participants provided written formal consent.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The data that support the findings of this study are available from the Center for Tropical Disease Research, Fudan University, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Center for Tropical Disease Research, Fudan University.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
REFERENCES

1. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. *Lancet* 2016;388:1081–8.

2. WHO. New Hepatitis data highlight need for urgent global response. 2017. http://www.who.int/mediacentre/news/releases/2017/global-hepatitis-report/en/ (accessed 18 May 2017).

3. WHO. WHO issuing updated guidelines for treatment of hepatitis C infection. 2016. http://www.who.int/hepatitis/news-events/hepatitis-c-guidelines-2016-story/en/ (accessed 20 Jul 2016).

4. Westbrook RH, Dusheiko G. Natural history of hepatitis C. *J Hepatol* 2014;61:S58–68.

5. Terrault NA. Sexual activity as a risk factor for hepatitis C. *Hepatology* 2002;36:S99–105.

6. Xia X, Luo J, Bai J, et al. Epidemiology of hepatitis C virus infection among injecting drug users in China: a systematic review and meta-analysis. *Public Health* 2008;122:990–1003.

7. Beyrer C, Razak MH, Lisam K, et al. Overland heroin trafficking routes and HIV-1 spread in south and South-East Asia. *AIDS* 2000;14:75–83.

8. Zhou YB, Wang QX, Yang MX, et al. Geographical variations of risk factors associated with HCV infection in drug users in Southwestern China. *Epidemic Inf* 2016;144:1291–300.

9. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. *Clin Infect Dis* 2012;55 Suppl 1:S33–42.

10. Berenguer J, Rivero A, Jarrín I, et al. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: prevalence and patient characteristics. *Open Forum Infect Dis* 2016;3:ofw058.

11. Sułkowski MS. Viral hepatitis and HIV coinfection. *J Hepatol* 2008;48:533–47.

12. Organization WHG. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: updated version. 2016. http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/ (accessed 16 Mar 2017).

13. Fu Y, Wang Y, Xie W, et al. New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. *J Viral Hepat* 2011;18:42–52.

14. Gao X, Cui Q, Shi X, et al. Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. *BMJ Infect Dis* 2011;11:88.

15. Dong C, Huang ZJ, Martin MC, et al. The impact of social factors on human immunodeficiency virus and hepatitis C virus co-infection in a minority region of Si-chuan, the people’s Republic of China: a population-based survey and testing study. *PLoS One* 2014;9:e101241.

16. Zhou YB, Wang QX, Liang S, et al. Geographical variations in risk factors associated with HIV infection among drug users in a prefecture in Southwest China. *Infect Dis Poverty* 2015;4:38.

17. Chaoilang W. Comparison between colloidal gold and enzyme-linked immunosorbent assay of hepatitis C virus antibody. *Clin Med Eng* 2011;18:701–2.

18. Chen YS, Li L, Cui FQ, et al. A sero-epidemiological study on hepatitis C in China. *Chin J Epidemiol* 2011;32:888–91.

19. Zhao LR, Duan S, Duan QX, et al. Prevalence and correlation of hepatitis C virus infection among ethnic minority villagers in Dehong prefecture, Yunnan province. *Chin Prev Med* 2012;24:1491–500.

20. Uccellini L, Tseng FC, Monaco A, et al. HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. *Hepatology* 2012;56:86–94.

21. Paez Jimenez A, Mohamed MK, Eldin NS, et al. Injection drug use is a risk factor for HCV infection in urban Egypt. *PLoS One* 2009;4:e7193.

22. Alter MJ, Mj A. Epidemiology of hepatitis C virus infection. *World J Gastroenterol* 2007;13:2436–41.

23. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. *Liver Int* 2011;31:30–60.

24. Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. *J Hepatol* 2014;61:1137–44.

25. Iversen J, Wand H, Topp L, et al. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. *Am J Public Health* 2013;103:1436–44.

26. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. *Addiction* 2011;106:1978–88.

27. Van Den Berg C, Smit C, Van Brussel G, et al. Full participation in harm reduction drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeleke District, Dar-es-Salaam, 2011. *Int J Drug Policy* 2013;24:78–81.

28. Gao X, Cui Q, Shi X, et al. Prevalence and trend of hepatitis C virus infection among blood donors in chinese mainland: a systematic review and meta-analysis. *BMJ Infect Dis* 2011;11:88.

29. Qian HZ, Yang Z, Shi X, et al. Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China Integrated Programs for Research on AIDS. *J Infect Dis* 2005;192:1694–700.

30. Flisiak R, Halota W, Horban A, et al. Prevalence and risk factors of HCV infection in Poland. *Eur J Gastroenterol Hepatol* 2011;23:1213–7.

31. Bowring AL, Luhmann N, Pont S, et al. An urgent need to scale-up drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeleke District, Dar-es-Salaam, 2011. *Int J Drug Policy* 2013;24:78–81.

32. Lee MH, Yang HI, Jen CL, et al. Global epidemiology for hepatitis C virus infection: a survey of 23,820 residents in Taiwan. *Gut* 2011;60:1454–62.

33. Denniston MM, Jiles RB, Drobeniuc J, et al. Overland heroin trafficking and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. *Addiction* 2011;106:1978–88.

34. Lee MH, Yang HI, Jen CL, et al. Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan. *Am J Public Health* 2013;103:1436–44.

35. Triantafilou M, Guglielmi C, et al. Full participation in harm reduction drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeleke District, Dar-es-Salaam, 2011. *Int J Drug Policy* 2013;24:78–81.

36. Flisiak R, Halota W, Horban A, et al. Prevalence and risk factors of HCV infection in Poland. *Eur J Gastroenterol Hepatol* 2011;23:1213–7.

37. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. *Liver Int* 2011;31:30–60.

38. Martin NK, Vickerman P, Foster GR, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. *J Hepatol* 2014;61:1137–44.

39. Platt L, Easterbrook P, Gower E, et al. New trends of HCV infection in China: a systematic review and meta-analysis. *BMJ Infect Dis* 2011;11:88.